전체 8345
-
- Human Bone Marrow Failure at the Intersection of Inflammation and Cancer (NIH-Only)
-
- - Young, Neal S.
National Institutes of Health (U.S.) (2010/11/18) - - Category : NCI CCR Grand Rounds (NIH Only)
- - Young, Neal S.
- Dr. Young received his A.B. from Harvard and M.D. from the Johns Hopkins School of Medicine. Following his internal medicine residency at Massachusetts General Hospital, Dr. Young came first to the National Institutes of Health to learn protein biochemistry in the laboratory of Nobel Prize winner Christian Anfinsen. After a fellowship in hematology at Barnes Hospital of Washington University in St. Louis, Dr. Young returned to NHLBI for a second post-doctoral fellowship in molecular biology under Dr. Arthur Nienhuis. He developed an interest in aplastic anemia during this time and established an independent section in the former Clinical Hematology Branch to study human bone marrow failure, both its treatment and pathogenesis. Dr. Young has published almost 300 research articles and more than 100 reviews and book chapters; he has written or edited 10 monographs, including a novel textbook of hematology. Dr. Young is a member of many honorary societies, including the American Society of Clinical Investigation and the American Association of Physicians. He is a Master of the American College of Physicians and the recipient of many named lectureships in hematology and medicine. He is co-discoverer on seven patents relating to parvoviruses and also the detection of mutations in human single hematopoietic cells. Finally, Dr. Young has mentored dozens of post-doctoral fellows who now occupy professorial chairs in the United States, Europe, and Asia.
SELECTED REFERENCES:
1. Calado RT, Young NS. Telomere maintenance and human bone marrow failure. Blood 2008;111:4446？？？55.
2. Calado RT, Regal JA, Hills M, Yewdell WT, Dalmazzo LF, Zago MA, Lansdorp PM, Hogge D, Chanock SJ, Estey EH, et al.Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci U.S.A. 2009 January 27;106(4):1187-92.
NCI？？？s Center for Cancer Research (CCR) Grand Rounds is a weekly lecture series addressing current research in clinical and molecular oncology. Speakers are leading national and international researchers and clinicians proposed by members of the CCR Grand Rounds Planning Committee and others within the CCR community and approved by the CCR Office of the Director. Lectures occur every Tuesday from 8:00 to 9:00 a.m. in Lipsett Amphitheater in the Clinical Center building on the NIH campus September through July with exceptions around holidays and major cancer meetings. The lecture schedule is posted on various calendars of events, including at the following link:
http://www.bethesdatrials.cancer.gov/health-care-professionals/grand-rounds.aspx
Human Bone Marrow Failure at the Intersection of Inflammation and Cancer (NIH-Only)
-
- Town Hall Meeting and Information Session: BTRIS, the NIH Biomedical Translational Research Information System
-
- - Shawn Murphy, MD, PhD (2010/11/18)
- - Category : Special
- The Biomedical Translational Research Information System (BTRIS) team invites you to a series of lectures focused on informatics in biomedical and translational research. This series brings leading 詮？gures in the study and use of translational information systems from academic centers across the U.S. and will promote discussion about the future of informatics at the Clinical Center.
Learn more about how BTRIS will be developed, opportunities for investigators to participate in its design, and project goals.
For more information, visit http://btris.nih.gov
Town Hall Meeting and Information Session: BTRIS, the NIH Biomedical Translational Research Information System
-
- Recombinant DNA Advisory Committee (RAC) June 2009 - Day 1
-
- - Office of Biotechnology Activities (2010/11/18)
- - Category : Recombinant DNA Advisory Committee
- The RAC is a technical committee whose goal is to consider the current state of knowledge and technology regarding recombinant DNA. This includes review of human gene transfer trials, and an assessment of the ability of DNA recombinants to survive in nature and the potential for transfer of genetic material to other organisms. It also considers hypothetical hazards and methods for monitoring and minimizing risks. Approximately one-third of the 15 members do not have scientific expertise but represent public interests and attitudes. This balance is intended to provide a forum for open public debate of social and scientific issues attendant to recombinant DNA research. The RAC has been overwhelmingly successful in achieving this goal.
For more information, visit the
Recombinant DNA Advisory Committee (RAC) Conference Web Site
Recombinant DNA Advisory Committee (RAC) June 2009 - Day 1
-
- Addressing Health Disparities in GLBT Populations (NIH-Only)
-
- - Deborah Bowen, Jesus Ramirez-Valles, Ronald Stall, Raynard Kington and Justin Hentges (2010/11/18)
- - Category : Diversity (NIH Only)
- Noons-in-June, the Annual NIH Gay, Bisexual, Lesbian and Transgender (GBLT) Pride Month
Theme: Addressing Health Disparities in GLBT Populations ？？？ Panel Discussion
Panel members: Dr. Deborah Bowen, Boston University Dr. Jesus Ramirez-Valles, University of Chicago Dr. Ronald D. Stall, University of Pittsburgh
Opening Remarks and Introduction of panel members: Dr. Raynard Kington, Director (Acting)
Closing Remarks: Justin D. Hentges, Chair, Salutaris
Addressing Health Disparities in GLBT Populations (NIH-Only)
-
- Regulation of Immunoglobulin Heavy Chain Gene Transcription and Recombination
-
- - Dr. Ranjan Sen, Chief, Laboratory of Cellular and Molecular Biology and Chief, Gene Regulation Section, National Institute on Aging, NIH (2010/11/18)
- - Category : Immunology
- After receiving his Ph.D. in chemistry from Columbia University, Dr. Sen joined the now-legendary laboratory of Dr. David Baltimore at M.I.T. and the Whitehead Institute. This was arguably one of the golden ages of molecular immunology, and Ranjan was at the forefront as he defined the post-translational mechanism by which the transcription factor NF-kB is activated (Sen, R. and Baltimore, D.: Inducibility of immunoglobulin enhancer-binding protein NF kB by a posttranslational mechanism. Cell 47: 921-928, 1986.), elucidating a signal transduction pathway that is an integral part of nearly every immune cell receptor system.
As a Professor of Biology at Brandeis University, Dr. Sen continued to develop his interest in gene regulation, especially as it applied to the transcription factors (NF-kB, OCT, NFAT, etc) and DNA motifs that control early events in lymphocyte development and immunoglobulin rearrangement. In 2003, he moved to his present position as Chief, Laboratory of Cellular and Molecular Biology, National Institute on Aging in Baltimore. Among his current interests----the chromatin modifications that play a role in controlling and orchestrating immunoglobulin recombination.
There is a relatively hidden gold mine of outstanding immunology occurring at the NIA, lead in no small part by Ranjans ongoing and enthusiastic efforts to understand the molecular details of lymphocyte development. Treat yourselves. Come and be both entertained and educated by this dynamic speaker as he describes his exciting work.
http://www.grc.nia.nih.gov/branches/irp/rsen.htm
For more information, visit
The Immunology Interest Group
Regulation of Immunoglobulin Heavy Chain Gene Transcription and Recombination
-
- Genetic Syndromes Associated with KIT or PDFGRA Non-Mutant Pediatric GISTs
-
- - Dr. Constantine Stratakis, National Institute of Child Health and Human Development, NIH (2010/11/18)
- - Category : Special
- The 3rd Pediatric and Wildtype GIST Clinic Invitational Lecture
The Pediatric and Wildtype GIST clinic at the National Institutes of Health (NIH) is a collaborative effort between clinicians, research scientists and advocates, who share the goal of helping young patients with Gastrointestinal Stromal Tumor.
For more information, visit
http://www.pediatricgist.cancer.gov
Dr. Constantine A. Stratakis
Chief, Unit of Genetics & Endocrinology
National Institute of Child Health and Human Development
Genetic Syndromes Associated with KIT or PDFGRA Non-Mutant Pediatric GISTs
-
- CC Grand Rounds: (1) Updates in the Pathogenesis and Therapy of Sepsis, (2) Sepsis: Another Look at Pathogenesis
-
- - Suffredini, Anthony F.
National Institutes of Health (U.S.) (2010/11/18) - - Category : Clinical Center Grand Rounds
- - Suffredini, Anthony F.
- Clinical Center Grand Rounds
Anthony F. Suffredini, MD
Senior Investigator and Associate Chief, Critical Care Medicine Department, CC
Robert Munford, MD
Senior Clinician, Laboratory of Clinical Infectious Diseases, NIAID
For more information, visit
http://www.cc.nih.gov/about/news/grcurrent.html
CC Grand Rounds: (1) Updates in the Pathogenesis and Therapy of Sepsis, (2) Sepsis: Another Look at Pathogenesis
-
- Neurobiology of Rett Syndrome and Related Disorders
-
- - Zoghbi, Huda.
National Institutes of Health (U.S.) (2010/11/18) - - Category : Wednesday Afternoon Lectures
- - Zoghbi, Huda.
- Rett syndrome is a postnatal developmental disorder characterized by stagnation of normal development and loss of acquired skills by 12-18 months of age. Although Rett syndrome is sporadic in over 99% of the cases, it is a genetic disorder caused by mutations in the X-linked gene encoding methyl-CpG-binding protein 2 (MeCP2). Loss of MeCP2 function in ~50% of neurons (due to random X chromosome inactivation [XCI]), causes classic Rett syndrome which is characterized by loss of language and social interaction skills, cognitive impairment, balance problems, seizures, tremors, stereotyped repetitive hand movements, and autonomic dysfunction.
Girls with favorable XCI patterns manifest only partial features of the syndrome and may present with either classic autism or mild mental retardation with or without seizures and tremors. Doubling of MeCP2 levels also causes a progressive neurological syndrome that shows overlapping features with Rett syndrome. The use of accurate genetic models of Rett and the duplication syndrome is providing insight about the pathogenic effects of MeCP2 dysfunction.
Data demonstrating the mechanism underlying the duplication phenotype, the role of MeCP2 in specific neurons, and the transcriptional alterations resulting from MeCP2 dysfunction will be presented
The NIH Directors Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide.
Neurobiology of Rett Syndrome and Related Disorders
-
- Recombinant DNA Advisory Committee (RAC) June 2009 - Day 2
-
- - Office of Biotechnology Activities (2010/11/18)
- - Category : Recombinant DNA Advisory Committee
- The RAC is a technical committee whose goal is to consider the current state of knowledge and technology regarding recombinant DNA. This includes review of human gene transfer trials, and an assessment of the ability of DNA recombinants to survive in nature and the potential for transfer of genetic material to other organisms. It also considers hypothetical hazards and methods for monitoring and minimizing risks. Approximately one-third of the 15 members do not have scientific expertise but represent public interests and attitudes. This balance is intended to provide a forum for open public debate of social and scientific issues attendant to recombinant DNA research. The RAC has been overwhelmingly successful in achieving this goal.
For more information, visit the
Recombinant DNA Advisory Committee (RAC) Conference Web Site
Recombinant DNA Advisory Committee (RAC) June 2009 - Day 2
-
- DDM - Dealing with Difficult People (NIH Only)
-
- - Sandy Crowe (2010/11/18)
- - Category : DDM Seminar Series (NIH Only)
- 2008-2009 Deputy Director for Management (DDM) Seminar Series
Click here to download a Survey about this DDM Seminar. Information will be used to evaluate the program and improve future seminars. PowerPoint slides for this event can be downloaded here.
Since 1986 Sandra Crowe has been using her people, public speaking, and communications skills to present quality programs to numerous federal, corporate, and association based organizations. Her purpose is to create awareness of ineffective behaviors and to provide methodologies and action steps to offset them while redirecting behavior toward more uplifting interactions between people.
Ms. Crowe is the author of the popular book, ？？？Since Choking Isn？？？t an Option？？？Common Problems and Uncommon Solutions？？？ and is the founder of a communications/networking specialty company called Powerlunch which has been written up in both The Washington Post and The New York Times. In addition, she has hosted her own television show called Stress Busters which was broadcast weekly on Washington, D.C. Cable Television. Her Powerlunch story was featured in the book Chicken Soup for the Soul at Work.
During her presentation for NIH, ？？？Dealing With Difficult People ？？？Common Problems and Uncommon Solutions,？？？ Sandra Crowe will be sharing her insights about the following: Defining ？？？difficult people？？？- Understanding the dynamics of difficult relationships, specifically your role in it
- Determining what to do when faced with a difficult relationship
- 6 practical steps that can be taken to navigate difficult situations
- 3 steps that you can use in ANY difficult scenario
- How to give feedback to change behavior
- How to handle resistance pitfalls
- Cementing good relationships
The DDM Seminar Series is open to all NIH employees and there is no need to pre-register for the event.
http://www.ddmseries.od.nih.gov
DDM - Dealing with Difficult People (NIH Only)
-
- The Fifth David S. Finbloom Lecture in Immunology
-
- - Vogel, Stefanie N.
Center for Biologics Evaluation and Research (U.S.) (2010/11/18) - - Category : David S. Finbloom
- - Vogel, Stefanie N.
- The Center for Drugs and the Center for Biologics, FDA, in conjunction with the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, organized this seminar series to honor the memory of our friend and colleague, Dr. David Finbloom.
This year marking the 10 year anniversary since the loss of our colleague, there will be several presentations marking the occasion:
Dr. Stefanie Vogel, Professor of Microbiology and Immunology at the University of Maryland Medical Center, will speak on The role of TLR4 in the host response to Respiratory Syncytial Virus (RSV) infection
Dr. Michael David, Professor of Biology at the University of California San Diego, will speak on The IFN/STAT1 axis in T cell Development
Dr. Andrew C. Larner, Professor of Biochemistry & Molecular Biology at the Virginia Commonwealth University School of Medicine, will speak on The Role of the JAK/STAT Pathway in Mitochondrial Function
Dr. Paul L. Fox, Professor of Molecular Medicine at the Cleveland Clinic Lerner Research Institute, will speak on Translational Control of Macrophage Gene Expression by Interferon-gamma
The Fifth David S. Finbloom Lecture in Immunology
-
- NCI Board of Scientific Advisors - June 2009
-
- - NCI Board of Scientific Advisors. Meeting (2010/11/18)
- - Category : NCI Board of Scientific Advisors
Provides scientific advice on a wide variety of matters concerning scientific program policy, progress, and future direction of the NCIs extramural research programs, and concept review of extramural program initiatives.
For more information, visit
http://deainfo.nci.nih.gov/advisory/bsa.htm
NCI Board of Scientific Advisors - June 2009
-
- Challenges in Human Papillomavirus Infection: HIV Co-infection and HPV Vaccines (NIH-Only)
-
- - Joel Palefsky, M.D., C.M., F.R.C.P., UCSF Clinical and Translational Sciences Institute (2010/11/18)
- - Category : NCI CCR Grand Rounds (NIH Only)
- Dr. Palefsky is Professor of Medicine at UCSF School of Medicine. Dr. Palefsky completed his undergraduate medical training and training in Internal Medicine at McGill University and completed his fellowship in Infectious Diseases at Stanford University. He is an internationally recognized expert on the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections, particularly in the setting of HIV infection. He is the Director of the worlds first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic at the UCSF Cancer Center. He has pioneered diagnostic and treatment methods for anal intraepithelial neoplasia and has been an advocate for anal screening in high-risk populations to prevent anal cancer. He is the head of the HPV Working Group of the AIDS Malignancy Consortium. He heads the Special Populations Committee of the American Society for Colposcopy and Cervical Pathology and is co-director of the Cancer and Immunology Program of the UCSF Comprehensive Cancer Center. He is the author of over 190 publications.
Dr. Palefsky？？？s ongoing projects focus on DNA tumor virus infection of the epithelium, specifically human papillomavirus (HPV) and Epstein-Barr virus (EBV). His work on HPV focuses on understanding the molecular pathogenesis of HPV-related neoplasia, the natural history of HPV infection in HIV-positive men and women; characterization of a new clinical entity, anal intraepithelial neoplasia (AIN) and its relationship to anal cancer; and development of novel approaches to prevent and treat anogenital HPV infection. His group continues to publish much of the world？？？s literature on the prevalence and incidence of anal HPV infection and AIN in a variety of at-risk groups of men and women.
Over 50% of HIV-positive MSM develop high-grade AIN, the anal cancer precursor. Treatment of AIN could reduce the incidence of anal cancer, but is very challenging for a number of reasons. In the last few years, much of his group？？？s clinical research activities have focused on development of better approaches to treating AIN to prevent anal cancer. His laboratory is also continuing to develop a gene therapy approach that uses a plasmid encoding the HSV-1 thymidine kinase (TK) gene under the control of HPV E2-response elements to drive HPV-specific expression of TK.
Dr. Palefsky？？？s program on EBV, like the HPV program described above, is focused on epithelial infection. His studies focus on the EBV BMRF-2 protein which his group has shown to play an important role in entry into epithelial cells. His group is also continuing its work on dissemination of EBV to and among epithelial cells and has recently begun to focus more on the role of HIV co-infection in this process. His group has also expanded its work on molecular interactions between HPV and HIV using novel epithelial models and newer methods to study HPV biology, including the use of HPV pseudovirions.
NCI？？？s Center for Cancer Research (CCR) Grand Rounds is a weekly lecture series addressing current research in clinical and molecular oncology. Speakers are leading national and international researchers and clinicians proposed by members of the CCR Grand Rounds Planning Committee and others within the CCR community and approved by the CCR Office of the Director. Lectures occur every Tuesday from 8:00 to 9:00 a.m. in Lipsett Amphitheater in the Clinical Center building on the NIH campus September through July with exceptions around holidays and major cancer meetings. The lecture schedule is posted on various calendars of events, including at the following link:
http://www.bethesdatrials.cancer.gov/health-care-professionals/grand-rounds.aspx
Challenges in Human Papillomavirus Infection: HIV Co-infection and HPV Vaccines (NIH-Only)
-
- NIH Public Consultation on "Synthetic Nucleic Acids and the NIH Guidelines for Research Involving Recombinant DNA Molecules"
-
- - National Science Advisory Board for Biosecurity (U.S.) (2010/11/18)
- - Category : Recombinant DNA Advisory Committee
- In 2006, the National Science Advisory Board for Biosecurity, an advisory committee to the Secretary of the Department of Health and Human Services, the NIH Director and all Federal entities that conduct/support life sciences research published a report entitled ？？？？？？Addressing Biosecurity Concerns Related to the Synthesis of Select Agents.？？？？？？ 1 The report included a recommendation that the United States Government (USG) ？？？？？？examine the language and implementation of current biosafety guidelines to ensure that such guidelines and regulations provide adequate guidance for working with synthetically derived DNA and are understood by all those working in areas addressed by the guidelines.？？？？？？ The USG adopted this recommendation and asked NIH to review the NIH Guidelines for Research with Recombinant DNA (NIH Guidelines) to evaluate whether these guidelines need to be revised to address biosafety concerns for research with synthetic DNA. With the advice of the NIH Recombinant DNA Advisory Committee (RAC), which is responsible for advising the NIH Director on all aspects of recombinant DNA technology, including revisions to the NIH Guidelines, the following proposed changes were developed. As outlined in more detail below, the proposed changes will expand the scope of the NIH Guidelines to specifically cover nucleic acid molecules made solely by synthetic means. The changes apply to basic laboratory research and clinical research. In addition, changes were made to clarify the criteria for determining whether an experiment to introduce drug resistance into a microorganism raises important public health issues such that it must be reviewed by the RAC and approved by the NIH Director. Finally, the proposed amendments speak to the appropriate level of review for recombinant or synthetic experiments involving more than half but less than two-thirds of the genome of certain viruses in tissue culture. These changes were prompted by an increased understanding of the biology of certain viruses that demonstrate there may be biosafety risks with certain viruses that contain less than two-thirds of the viral genome.
For more information, http://oba.od.nih.gov/rdna/rdna.html
NIH Public Consultation on "Synthetic Nucleic Acids and the NIH Guidelines for Research Involving Recombinant DNA Molecules"
-
- CC Grand Rounds: (1) Risks of Anesthesia and Sedation in Children, (2) Recent Innovations in Pain Management
-
- - Zenaide Quezado, MD and Andrew J. Mannes, MD (2010/11/18)
- - Category : Clinical Center Grand Rounds
- Clinical Center Grand Rounds
Zenaide Quezado, MD
Chief, Department of Anesthesia and Surgical Services, CC
Andrew J. Mannes, MD
Staff Clinician, Department of Anesthesia and Surgical Services, CC
For more information, visit
http://www.cc.nih.gov/about/news/grcurrent.html
CC Grand Rounds: (1) Risks of Anesthesia and Sedation in Children, (2) Recent Innovations in Pain Management
-
- Molecular Mechanisms of Memory Loss in Alzheimers Disease
-
- - Karen Hsiao Ashe, MD, PhD, University of Minnesota (2010/11/18)
- - Category : Wednesday Afternoon Lectures
- About Dr. Hsiao Ashe？？？s Lecture:
？？？We have performed studies involving the creation of transgenic mouse models of Alzheimers disease in order to understand how the amyloid-？？ and tau proteins impair memory and cognition. The work has shown that the aggregates of amyloid-？？ and tau proteins which define Alzheimers disease neuropathologically do not cause cognitive deficits in mice. These investigations have led to the discovery of a form of the amyloid-？？ protein called A？？ star (A？？*) that disrupts cognitive function in mice and rats, and increases in humans before a diagnosis of Alzheimers disease has been made. We propose that Alzheimers disease begins when A？？* levels rise, triggering a cascade of events that culminates in neurodegeneration and dementia.？？？
The NIH Directors Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide.
Molecular Mechanisms of Memory Loss in Alzheimers Disease
-
- Symposium on the Future of Telehealth: Essential Technologies for Clinical Research and Care
-
- - Symposium on the Future of Telehealth
National Center for Research Resources (U.S.) (2010/11/18) - - Category : Conferences
- - Symposium on the Future of Telehealth
- This meeting will bring a diverse group of stakeholders from an array of institutions, organizations, agencies, and other sectors together to discuss ways to enhance the use of telehealth tools to expand clinical research in underserved areas.
For more information, visit http://events.internet2.edu/2009/NIH/index.html
Symposium on the Future of Telehealth: Essential Technologies for Clinical Research and Care
-
- Who Gets Posttraumatic Stress Disorder?
-
- - Koenen, Karestan C.
National Institutes of Health (U.S.) (2010/11/18) - - Category : Special
- - Koenen, Karestan C.
- NIMH Candidate for PTSD Tenure-Track Investigator
For more information, visit: http://intramural.nimh.nih.gov/careers/index.html
Who Gets Posttraumatic Stress Disorder?
-
- Invisible Wounds-Post-Traumatic Stress Disorder/Mild Traumatic Brain Injury: Military Perspective
-
- - Moore, David F.
National Institutes of Health (U.S.). Womens Health Special Interest Group. (2010/11/18) - - Category : Womens Health
- - Moore, David F.
- Womens Health Special Interest Group (WHSIG)
Intramural Program on Research on Womens Health
Sponsored by the NIH Office of Intramural Research
and the NIH Office of Research on Womens Health.
Come join your fellow NIH colleagues in a scientific exchange on issues related to the biology and pathology of sex and gender differences and effects on womens health.
For more information, visit
http://orwh.od.nih.gov
Invisible Wounds-Post-Traumatic Stress Disorder/Mild Traumatic Brain Injury: Military Perspective
-
- Stability and Plasticity of Regulatory T Cell Function (NIH Only)
-
- - Rudensky, Alexander.
National Institutes of Health (U.S.) (2010/11/18) - - Category : NIH Only
- - Rudensky, Alexander.
- NIH Mucosal Immunology Interest Group Seminar Series:
Alexander Rudensky has played a vital role in our understanding of CD4+ Foxp3+ regulatory T cells (Tregs). He and his group established the critical role for Foxp3 in the development, function, and maintenance of Tregs. Furthermore, they have undertaken studies to examine the TCR repertoire of Tregs versus T effector cells with the aim of determining the TCR specificity of Treg populations, have examined the transcriptional targets of foxp3, and have begun to assess the stability of the Treg phenotype in various settings. Most recently, his laboratory has discovered a role for the dicer-dependent microRNA pathway in preserving Treg function in inflammatory settings. Dr. Rudensky is a HHMI investigator and has received many awards and honors for his outstanding work. He is a world leader in the fields of immunology and of regulatory T cell biology, and will undoubtedly deliver a seminar that you will not want to miss.
For more information see Dr. Rudenskys web site: http://www.mskcc.org/mskcc/html/88987.cfm
Stability and Plasticity of Regulatory T Cell Function (NIH Only)